Peijia Medical s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
News provided by
Share this article
Share this article
SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne
® Transcatheter Aortic Valve Replacement System (hereinafter referred to as TaurusOne
® ) developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC ( NMPA ) with registration number GXZZ 20213130275.
Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne
26 aprile 2021 09:25
Fonte: Adnkronos
#salute-e-benessere
- SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as TaurusOne® ) developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC ( NMPA ) with registration number GXZZ 20213130275.
Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne® registration clinical trial completed by National Centre for Cardiovascular Disease, Fuwai Hospital, The Second Affiliated Hospital ZheJiang University School of Medicine, West China Hospital of Sichuan University, General Hospital of Northern Theater Command, the Second Affilia
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Peijia Medical’s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
April 25, 2021 GMT
SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne® Transcatheter Aortic Valve Replacement System (hereinafter referred to as “TaurusOne®”) developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medical Products Administration of the PRC (“NMPA”) with registration number GXZZ 20213130275.
Academician Gao Runlin of Fuwai Hospital Chinese Academy of Medical Sciences served as Principal Investigator for the TaurusOne® registration clinical trial completed by National Centre for Cardiovascular Disease, Fuwai Hospital, The Second
SUZHOU, China, April 24, 2021 /PRNewswire/ A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne Transcatheter
Peijia Medical s TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.